Quantcast
Last updated on April 24, 2014 at 13:44 EDT

Latest ADASUVE Stories

2014-03-19 08:30:28

Notes Secured by Royalties and Milestones on U.S. Sales of ADASUVE® MOUNTAIN VIEW, Calif., March 19, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes"). The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE(®) (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S....

2014-03-06 16:27:30

Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., March 6, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and...

2013-11-06 16:31:15

Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Nov. 6, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2013. The net loss for the third quarter was $12.4 million compared to $6.9 million during the same quarter in 2012. The net loss for the nine months ended September 30, 2013 and 2012, was $33.9 million and...

2013-08-08 16:27:36

Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Aug. 8, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported preliminary financial results for the quarter ended June 30, 2013. The preliminary net loss for the quarter ended June 30, 2013, was $3.4 million compared to $7.0 million during the same quarter in 2012. The preliminary net loss for the six months ended June 30,...

2013-05-14 16:27:11

Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., May 14, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter March 31, 2013. The net loss for the quarters ended March 31, 2013 and 2012, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were $20.7 million and $3.8 million,...

2013-05-08 08:30:57

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. and MOUNTAIN VIEW, Calif., May 8, 2013 /PRNewswire/ -- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE...

2013-03-26 16:28:28

Management to Review Results and Provide Business Updates in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., March 26, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter and full year ended December 31, 2012. The net loss for the quarters ended December 31, 2012 and 2011, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were...

2012-12-21 16:22:51

MOUNTAIN VIEW, Calif., Dec. 21, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE(®) (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato(®) delivery system with the antipsychotic drug, loxapine. The Staccato system is a hand-held inhaler that delivers a drug...

2012-11-06 16:28:14

MOUNTAIN VIEW, Calif., Nov. 6, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended September 30, 2012 and provided a business update. The net loss for the quarters ended September 30, 2012 and 2011, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were $6.9 million and $13.4 million, respectively. The net loss for the nine-month periods ended September 30, 2012...

2012-08-08 10:25:34

MOUNTAIN VIEW, Calif., Aug. 8, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended June 30, 2012 and provided a business update. The net loss for the quarters ended June 30, 2012 and 2011, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were $7.0 million and $9.0 million, respectively. The net loss for the six-month periods ended June 30, 2012 and 2011 were $10.8...